JUVELOOK 50 mg PDLLA + HA Hybrid Biostimulator
JUVELOOK 50 mg PDLLA + HA Hybrid is a Biostimulators product from Juvelook, listed by Renz Medical for aesthetic product procurement in Pakistan. It is marked for professional use, so suitability and handling should be confirmed by a qualified practitioner.
Professional pricing is available to verified clinic accounts.
JUVELOOK 50 mg PDLLA + HA Hybrid quick facts
- Brand
- Juvelook
- Category
- Biostimulators
- Availability
- In stock
- SKU
- Not specified
- Access
- Professional use only
Product overview
JUVELOOK 50 mg is a professional hybrid vial containing 42.5 mg poly-D,L-lactic acid (PDLLA) plus 7.5 mg hyaluronic acid (HA), supplied as one sterile vial for use under the current manufacturer IFU.
Key characteristics
- Hybrid formulation combines PDLLA microspheres with an HA component.
- Requires professional preparation, patient selection, and administration according to the exact product IFU.
Product features
- Exact 50 mg vial identified.
- PDLLA and HA quantities are disclosed.
- Manufacturer product image is matched to the 50 mg vial.
Composition / ingredients
- Poly-D,L-lactic acid (PDLLA): 42.5 mg.
- Hyaluronic acid (HA): 7.5 mg.
- Total stated content: 50 mg per vial.
Professional applications
- Use only for the indication and treatment areas authorized for the exact 50 mg presentation in the relevant market.
- Do not use the storefront description as a treatment protocol.
Presentation
- One 50 mg vial containing 42.5 mg PDLLA + 7.5 mg HA.
Safety and handling
- Do not use when the current manufacturer IFU or local labeling excludes the patient, indication, or treatment area.
- Do not use through infected or actively inflamed tissue. Screen for relevant allergies, medical conditions, medicines, pregnancy or breastfeeding, and prior implants according to the IFU.
- Intravascular administration can cause serious complications. Administration requires product-specific training and detailed anatomical knowledge.
Use and handling
Preparation and administration must follow the exact product presentation's current manufacturer IFU. Renz Medical does not publish injection protocols on storefront product pages.
Storage
- Store and transport exactly as stated on the supplied product label and current manufacturer IFU.
- Keep the product in its original packaging and do not use after the stated expiry date.
Frequently asked questions
What is JUVELOOK 50 mg PDLLA + HA Hybrid?
JUVELOOK 50 mg PDLLA + HA Hybrid is a Biostimulators product from Juvelook, listed by Renz Medical for aesthetic product procurement in Pakistan. It is marked for professional use, so suitability and handling should be confirmed by a qualified practitioner.
What is the price of JUVELOOK 50 mg PDLLA + HA Hybrid in Pakistan?
Pricing for JUVELOOK 50 mg PDLLA + HA Hybrid is available to eligible verified clinic accounts.
Is JUVELOOK 50 mg PDLLA + HA Hybrid currently available?
JUVELOOK 50 mg PDLLA + HA Hybrid is currently marked in stock in the Renz Medical catalog. Stock is checked again when an order is reviewed.
Is JUVELOOK 50 mg PDLLA + HA Hybrid for professional use?
JUVELOOK 50 mg PDLLA + HA Hybrid is marked for professional use. A qualified practitioner should confirm intended use, handling, contraindications and local professional requirements.
Which JUVELOOK 50 mg PDLLA + HA Hybrid options are listed?
The currently listed options are 50 mg / vial. Select an option on the product page to confirm its price and availability.
What should I verify before ordering JUVELOOK 50 mg PDLLA + HA Hybrid?
Confirm the Juvelook product name, SKU, pack or variant, current stock status and manufacturer instructions. On receipt, verify the seal, batch and expiry information before professional use.
Which presentation of JUVELOOK is listed?
The listing is for one 50 mg vial containing 42.5 mg PDLLA and 7.5 mg HA.
Who may order JUVELOOK from Renz Medical?
This is a professional-use clinical product. A clinic account and professional verification are required before checkout, and final availability is confirmed before dispatch.